Multiple Sclerosis
Conditions
Keywords
Multiple Sclerosis, IFB 1a
Brief summary
Our study aimed to investigate the effect of interferon beta 1a on the clinical and immunological parameters in Egyptian relapse-remitting multiple sclerosis patients
Detailed description
Until recently, relapsing-remitting multiple sclerosis (RRMS) was considered a homogeneous form of multiple sclerosis (MS). Variability both in the immunopathology of active demyelinating lesions in MS and in response to immunomodulatory treatments has demonstrated that RRMS is a heterogeneous form of MS. An overwhelming number of trials have supported the use of interferon-β (IFN-β) as a first-line immunomodulatory treatment in RRMS. Approximately 30% of IFN-β treated RRMS patients are non-responders (NR) to treatment. Despite vast clinical experience in the use of IFN-β, its mechanisms of action have not been fully clarified. Interleukin-17 (IL-17) is a proinflammatory cytokine that is secreted by a lineage of T cells named Th17 cells. The Th17 chemokine pathways are essential for the development of central nervous system (CNS) autoimmune diseases such as MS. A high IL-17 concentration in the serum. of people with RRMS is associated with nonresponse to IFN-β therapy. Some animal and human studies have shown that IFN-β inhibits the activity of Th17 cells.
Interventions
OTHERBlood sample collection
5 ml of blood samples were withdrawn from RRMS patients
Sponsors
German University in Cairo
Study design
Observational model
COHORT
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
18 Years to 50 Years
Healthy volunteers
No
Inclusion criteria
* Age between 18 and 50 years at time of signing informed consent form. * Relapsing- remitting multiple sclerosis as per the McDonald 2017 criteria, including an MRI brain satisfying the 2017 radiological criteria. * Kurtzke EDSS step 0.0 - 6.0. * At the time of screening, being treated with a stable dose of Interferon Beta 1a for at least 6 months.
Exclusion criteria
* they had been treated in the last 30 days with methylprednisolone * they had changed their IFN-β preparation within the last 18 months * they had other chronic diseases associated with MS * they had been previously treated with immunosuppressive agents
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Correlation between IL17 levels and patients' response to interferon beta 1a as measured by ELISA | Patients were treated with INF B 1a for at least 6 months | Anti-inflammatory and disease activity biomarkers |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Correlation between IL 22 levels and patients' response to interferon beta 1a, measured by ELISA | Patients were treated with INF B 1a for at least 6 months | Anti-inflammatory and disease activity biomarkers |
| Correlation between Expanded Disability Status Scale and patients' response to interferon beta 1a | Patients were treated with INF B 1a for at least 6 months | Determination disability level (0 - 6), The lowest value means that it is best outcome and the highest value is the worst outcome. |
| Correlation between malondialdehyde levels and patients' response to interferon beta 1a | Patients were treated with INF B 1a for at least 6 months | oxidative stress biomarkers |
| Correlation between MRI load and Patients' response to interferon beta 1a | Patients were treated with INF B 1a for at least 6 months | Determination of T2 lesions |
| Correlation between body mass index and patients' response to interferon beta 1 a | Patients were treated with INF B 1a for at least 6 months | Body weight measurement |
Countries
Egypt
Outcome results
None listed